Adaptive clinical trial designs can be easily supported by MedQIA’s reading processes and information systems. For example, MedQIA supports cancer immunotherapy trials with adaptive treatment-switching designs involving multiple cell lines, with the following capabilities:
- Response assessment using re-baselining after disease progression and a switch in therapy.
- Real-time reads to direct therapy switched on progression/response.
This gives Sponsors flexibility in evaluating multiple therapies within a single trial, saving time and cost. Sponsors can leverage centralized outcome reads for reliable treatment switch decisions.